FDA Reviewed Treatment for Aggressive Prostate Cancer

Publication: KXAS-TV (NBC, Dallas-Fort Worth)
June 28, 2018

The FDA is reviewing approval of enzalutamide, a drug which lowered the risk of metastasis or death in men with non-metastatic hormone-resistant prostate cancer, according to a new study of 1,400 patients. Dr. Ashley Ross, medical oncologist at Texas Urology Specialists–Plano, discusses the trial.

Click here to watch the full story.